Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ricorfotide vedotin
- Development stage
- Phase 1
- Lead developer
- Coherent Biopharma
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**Ricorfotide vedotin (CBP-1008, Rico-V)** is a first-in-class dual-ligand **small molecule-drug conjugate (Bi-XDC)** developed by **Coherent Biopharma** using their proprietary Bi-XDC platform. It features two peptide ligands targeting **folate receptor alpha (FRα)** and **TRPV6** (an oncochannel overexpressed in tumors), conjugated to **MMAE (monomethyl auristatin E)**, a microtubule inhibitor payload, enabling tumor-specific delivery and cytotoxicity independent of FRα expression levels. With a low molecular weight of ~3.4 kDa (1/50th of typical ADCs), it is fully chemically synthesized for cost-effective manufacturing. It has demonstrated strong efficacy in platinum-resistant ovarian cancer (PROC) with ORR, DCR, and OS superior to historical standards, favorable safety (mild-moderate AEs, no ocular toxicity, minimal neuropathy), and activity in breast and endometrial cancers; it holds **Fast Track** designation in the US and is advancing to **Phase 3** in China for PROC and triple-negative breast cancer.
- Other names
- ricorfotide vedotin
02
Targets
FOLR1 (FRα)TRPV6 (Transient receptor potential cation channel subfamily V member 6)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ricorfotide vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ricorfotide vedotin.